Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

Pelthos Therapeutics (NYSE American: PTHS) will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026.

Rhea-AI Summary

Pelthos Therapeutics (NYSE American: PTHS) will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. A conference call and Q&A will be held at 8:00 a.m. Eastern Time the same day.

Investors can join via toll-free dial-in, international number, conference ID 13758894, or a live webcast at the provided URL.

Argus Mar 9 session

-0.30% close to close Open Argus

Details

News Market Reaction – PTHS

On Mar 9, the day this news came out, PTHS closed 0.30% below the previous close.

Data tracked by StockTitan Argus for the Mar 9 session.

Market Context

This announcement sets March 19, 2026 for Pelthos’s Q4 and full-year 2025 results, with a conference...

Analysis

This announcement sets March 19, 2026 for Pelthos’s Q4 and full-year 2025 results, with a conference call at 8:00 a.m. Eastern Time. Investors will be able to assess progress on commercializing ZELSUVMI and integrating recent financing and acquisition moves. Regulatory filings highlight a going concern qualification, an accumulated deficit near $43.1 million, and an active $200,000,000 shelf, making cash runway, revenue trends, and any capital-raising updates key items to watch in the upcoming report.

Key Figures

Earnings date: March 19, 2026 Conference time: 8:00 a.m. Eastern Time Toll-free number: 1-877-451-6152 +2 more

Earnings date

March 19, 2026

Scheduled Q4 and full-year 2025 results release

Conference time

8:00 a.m. Eastern Time

Start of earnings conference call

Toll-free number

1-877-451-6152

U.S. dial-in for earnings call

International number

1-201-389-0879

International dial-in for earnings call

Conference ID

13758894

Access code for earnings conference call

Historical Context

5 past events · Latest: Feb 23

5 events

1. Feb 23

   Conference appearance

   24h Move

   +5.0%

   CEO presentation at Oppenheimer healthcare conference with webcast and meetings.

2. Jan 13

   Debt financing

   24h Move

   -1.3%

   Up to $50M senior secured term loan facility to support product launches.

3. Jan 05

   Product acquisition

   24h Move

   -9.0%

   Acquisition of FDA-approved Xeglyze head-lice treatment for $1.8M.

4. Dec 23

   Board appointment

   24h Move

   -1.8%

   Appointment of experienced finance executive Andrew Einhorn to board roles.

5. Dec 04

   Access agreement

   24h Move

   +0.6%

   PBM agreement expanding ZELSUVMI access to over 20M covered lives.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to hold a conference call at 8:00 a.m. ET

DURHAM, N.C., March 09, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. The company will hold a conference call followed by a question-and-answer period at 8:00 a.m. Eastern Time.

Details for the conference call can be found below:

Date:	Thursday, March 19, 2026
Time:	8:00 a.m. Eastern Time
Toll Free:	1-877-451-6152
International:	1-201-389-0879
Conf.ID:	13758894
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1753536&tp_key=4e91699655

About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI™ (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat Molluscum contagiosum. The company’s portfolio of assets includes Xepi® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and Xeglyze® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Contacts
Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Pelthos Therapeutics (PTHS) report Q4 and full year 2025 results?

Pelthos Therapeutics will report results on March 19, 2026 with a conference call at 8:00 a.m. ET. According to Pelthos Therapeutics, the company will release fourth quarter and full year 2025 financial results and host a follow-up Q&A for investors.

How can investors join the Pelthos Therapeutics (PTHS) earnings call on March 19, 2026?

Investors may join by dialing the toll-free number or international line using conference ID 13758894. According to Pelthos Therapeutics, a live webcast link is also provided for online access during the 8:00 a.m. ET call.

Will Pelthos Therapeutics (PTHS) provide a webcast for the March 19, 2026 call?

Yes. A live webcast will be available via the company's provided URL for the March 19, 2026 8:00 a.m. ET call. According to Pelthos Therapeutics, the webcast link allows investors to listen to the financial results and Q&A online.

What time is the Pelthos Therapeutics (PTHS) conference call for the Q4 2025 results?

The conference call is scheduled for 8:00 a.m. Eastern Time on March 19, 2026. According to Pelthos Therapeutics, the call will include presentation of results followed by a question-and-answer period for investors and analysts.

What information should shareholders expect from Pelthos Therapeutics' (PTHS) March 19, 2026 announcement?

Shareholders should expect fourth quarter and full year 2025 financial results and a management Q&A on the March 19, 2026 call at 8:00 a.m. ET. According to Pelthos Therapeutics, the company will present financial performance details and answer investor questions.